Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy

2010 ◽  
Vol 20 (2) ◽  
pp. 248-254 ◽  
Author(s):  
George Bozas ◽  
Evangelos Terpos ◽  
Dimitra Gika ◽  
Alexandra Karadimou ◽  
Meletios A. Dimopoulos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Platinum Based Chemotherapy ◽  
Transforming Growth Factor Β2 ◽  
Advanced Epithelial Ovarian Cancer ◽  
Endothelial Growth Factor

Coagulopathy, Blood Loss, and Vascular Endothelial Growth Factor in Advanced Epithelial Ovarian Cancer

2006 ◽  
Vol 107 (Supplement) ◽  
pp. 107S
Author(s):  
John P. Geisler ◽  
Georgiann C. Linnemeier ◽  
Michael C. Wiemann ◽  
John Broshears ◽  
Greg A. Miller ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Blood Loss ◽  
Epithelial Ovarian Cancer ◽  
Vascular Endothelial ◽  
Advanced Epithelial Ovarian Cancer ◽  
Endothelial Growth Factor

Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor β and vascular endothelial growth factor

2004 ◽  
Vol 14 (1) ◽  
pp. 82-88
Author(s):  
M. SÖNMEZER ◽  
M. GÜNGÖR ◽  
A. Ensari ◽  
F. Ortaç
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Epithelial Ovarian Cancer ◽  
Transforming Growth Factor ◽  
Prognostic Significance ◽  
Transforming Growth Factor Β ◽  
Vascular Endothelial ◽  
Clinicopathologic Factors ◽  
Endothelial Growth Factor

We aimed to evaluate the prognostic significance of microvessel density (MVD), vascular endothelial growth factor (VEGF), and transforming growth factor β (TGFβ), as well as to find out the relationship between MVD, and VEGF and TGFβ in epithelial ovarian cancer (EOC). Surgical specimens of 47 patients with stage I–IV primary EOC, who underwent extended surgical staging according to FIGO, were investigated. Five-μm thick tissue sections were immunostained with antibody to factor VIII-related antigen, and MVD was assessed at three separate areas of ×200 magnification. Expressions for VEGF and TGFβ were evaluated by immunohistochemical staining using related monoclonal antibodies. Results were correlated with clinicopathologic factors and survival. We did not find any correlation between MVD and clinicopathologic factors, or patient survival. Similarly, there was no association between the degree of VEGF staining and survival or clinicopathologic factors, except preoperative ascites volume, which was higher in patients showing moderate and intense VEGF staining than those with weak VEGF staining (P = 0.052). The expression of TGFβ was inversely correlated with preoperative CA-125 levels (P < 0.05). Furthermore, there was no correlation between MVD and the staining intensity of VEGF or TGFβ. In conclusion, angiogenesis does not appear as a prognostic factor in EOC. We suggest that VEGF is an important mediator of ascites formation, and that TGFβ, which is supposed to have tissue-specific actions in tumorigenesis, may have growth-inhibitory functions in EOC.

Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries

2017 ◽  
Vol 27 (6) ◽  
pp. 1088-1095 ◽  
Author(s):  
Blanca González-Palomares ◽  
Pluvio J. Coronado Martín ◽  
María Luisa Maestro de las Casas ◽  
Silvia Veganzones de Castro ◽  
Sara Rafael Fernández ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Serum Levels ◽  
Benign Tumors ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Worse Prognosis

ObjectiveThis study analyzed the relation of 5 single-nucleotide polymorphisms (SNPs) in the VEGF (vascular endothelial growth factor) gene in patients with epithelial ovarian cancer (EOC), compared with patients carrying benign tumors or healthy ovaries. We studied serum VEGF levels and the relation with SNPs and association between VEGF SNPs and haplotypes with progression-free survival (PFS) in patients with cancer.MethodsThe genotyping of VEGF gene polymorphisms (−2578 C/A, −1154 G/A, −460 T/C, +405 G/C, +936 C/T) was performed in DNA isolated from blood samples of 100 women. The different genotypes were evaluated by quantitative real-time polymerase chain reaction. Vascular endothelial growth factor protein concentration was assessed in serum using solid-phase sandwich enzyme-linked immunosorbent assay.ResultsWe found statistically significant differences in the distribution of VEGF genotypes among the 3 groups of patients: −2578 C/A between those with EOC and healthy ovary (P = 0.04), −460 T/C between those with EOC and healthy ovary (P = 0.03), and −460 T/C between those with benign tumors and healthy ovary (P = 0.02). Vascular endothelial growth factor serum levels were analyzed in patients with EOC. Higher levels were found in patients with clear cell carcinoma compared with those with serous, mucinous, or endometrioid tumors (P < 0.05). No clear association was observed between VEGF SNPs and serum VEGF levels. There was no significant correlation between VEGF SNPs and PFS. In haplotype analysis, CGTCT and CGTGT showed worse prognosis without reaching the statistical significance. CGCGC and AGTGC haplotypes had statistically significant differences among patients with EOC, benign tumors, and healthy ovaries (Ps = 0.046 and 0.041, respectively).ConclusionsThe distribution of VEGF genotypes was different in patients with EOC, compared with those with benign tumors or women with healthy ovaries. Vascular endothelial growth factor serum levels were higher in patients with clear cell carcinoma. No correlation was found with improved PFS, but CGTCT and CGTGT haplotypes showed worse prognosis.

scholarly journals Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer

2013 ◽  
Vol 1 (2) ◽  
pp. 197-201 ◽  
Author(s):  
TAKAFUMI WATANABE ◽  
MASAHIKO SHIBATA ◽  
HIROSHI NISHIYAMA ◽  
SHU SOEDA ◽  
SHIGENORI FURUKAWA ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Elevated Serum ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document